Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
International Institute of Nano and Molecular Medicine I²NM² is engaged in multifaceted research projects involving the creation of novel boroncontaining materials, devices and agents enhanced by nanotechnology with applications in medicine, related materials science and beyond. Research highlights include: FACULTY M. Frederick Hawthorne, Ph.D. Director Mark W. Lee, Jr., Ph.D. Assistant Director Satish Jalisatgi, Ph.D. Director of Research Operations Development of nano-sized molecular motors with biomedical applications. Development of catabolism-resistant pharmaceuticals based on carborane surrogate chemistry. Alexander Safronov, Ph.D. Research Assistant Professor Lalit Goswami, Ph.D. Research Assistant Professor Design, synthesis and characterization Yulia Sevryugina, Ph.D. Research Assistant Professor Lixin Ma, Ph.D. Assistant Professor of new, high-energy materials for energy storage in structural units ranging from nano dimensional to macroscale. Molecular Motors Development of advanced chemical storage systems for hydrogen storage based upon nanotechnology and hydride chemistry. Chemical Hydrogen Storage Boron Neutron Capture Therapy of Cancer First demonstration of the proof-of-principle for boron neutron capture therapy of cancer, arthritis and radiation mediated surgery (BNCT). Discrete molecular (monodisperse) nanoparticles which Drug Delivery carry multiple copies of, or a combination of, diagnostic and therapeutic agents for cell-specific delivery to malignant cells. 1514 RESEARCH PARK DR. COLUMBIA MO 65211 573-882-7016 WWW.NANOMED.MISSOURI.EDU Institute Facts The International Institute of Nano and Molecular Medicine (I²NM²) is a new campus- wi d e res earc h center dedicated to the discovery and application of fundamental and translational medical science based upon previously unexplored chemistry combined with nanotechnology and the biosciences. I²NM² will shortly become the international leader in the reinvigorated field of boron neutron capture therapy (BNCT), a cellselective binary radiation method for cancer, arthritis and evolving noninvasive surgical protocols. The BNCT program will be conducted with the dedicated neutron source recently constructed at the University of Missouri Research Reactor (MURR; the most powerful university-based research reactor in the world) and the use of the life sciences laboratory of the Dalton Cardiovascular Research Center, including small animal facilities. I²NM² is housed in its own 3 0, 0 0 0 f t ² la b or at o r y building in Reactor Park adjacent to the MURR and the Dalton Cardiovascular Research Center. The building houses several state of the art synthetic and analytical c h em i s t r y l a b or a t or i e s including world-class mass spectrometry facilities and a nuclear magnetic resonance laboratory. In addition to instituteowned facilities and instrumentation, the center will have access to several university instrumentation core facilities. These include additional NMR instr umentat ion, including 600 and 800 MHz NMR spectrometers, an electron microscopy facility with SEM, TEM and atomic force microscopy center. The unique strength of I²NM² is its new approach to medical inventions and its developing position as the strongest research facility for the development of boron neutron capture therapy of cancer in the world. These efforts are supported by superbly equipped laboratories with great strength in chemical synthesis coupled with nanoscience, biological chemistry, radiation biology and medicine. I²NM² will truly serve translational medicine. The Institute has been funded by the NIH, DOE, NSF, and Honeywell. and shares dual-use research projects with its subsidiary, Center for Borane Technology supported by the US Army (Picatinny Arsenal) and partnered with I 2 NM 2 . About the Director Dr. M. Frederick Hawthorne Fred Hawthorne, Ph.D., and founding Director of the International Institute of Nano and Molecular Medicine, came to MU from the University of California, Los Angeles in 2006. Hawthorne has led in the creation of the new field of polyhedral borane chemistry (carboranes, polyhedral borane anions, metallacarboranes and metallaboranes). These building blocks are finding use in nanoscience, biomedicine, catalysis and materials applications. An ongoing objective is the development of boron neutron capture therapy of cancer (BNCT) which Hawthorne will continue at the University of Missouri nuclear reactor and supporting facilities. For 32 years, Hawthorne served as the Editor-inChief of Inorganic Chemistry published by The American Chemical Society. Hawthorne has been honored by numerous national and international awards, honorary degrees and lectureships. He was the co-winner of the King Faisal International Prize in Science (2003), the highest scientific award of the Islamic world. In 2009 Hawthorne was named Priestley Medalist, the premier award of the American Chemical Society. He has published over 500 peer-reviewed papers and he holds 35 patents.Drug Delivry INTERNATIONAL INSTITUTE OF NANO AND MOLECULAR MEDICINE